Profile data is unavailable for this security.
About the company
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program is designed to enhance the ability of Superkines to treat immunologically cold tumors.
- Revenue in CAD (TTM)0.00
- Net income in CAD-25.47m
- Incorporated2015
- Employees16.00
- LocationMedicenna Therapeutics Corp2 Bloor St W., 7Th FloorTORONTO M4W 3E2CanadaCAN
- Phone+1 (416) 648-5555
- Fax+1 (416) 648-5555
- Websitehttps://www.medicenna.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Arch Biopartners Inc | 1.50m | -2.14m | 99.74m | -- | -- | -- | -- | 66.49 | -0.0341 | -0.0341 | 0.024 | -0.1025 | 0.5472 | -- | 0.6897 | -- | -78.01 | -214.82 | -- | -- | -- | -- | -142.55 | -180.45 | -- | -4.06 | -- | -- | 105.63 | -- | -136.30 | -- | -- | -- |
Oncolytics Biotech Inc | 0.00 | -28.21m | 112.98m | 29.00 | -- | 4.83 | -- | -- | -0.4027 | -0.4027 | 0.00 | 0.3046 | 0.00 | -- | -- | -- | -80.51 | -81.99 | -88.84 | -97.25 | -- | -- | -- | -- | -- | -- | 0.0468 | -- | -- | -- | -11.75 | -- | -40.52 | -- |
Zentek Ltd | 29.82k | -11.70m | 136.62m | 25.00 | -- | 6.75 | -- | 4,581.54 | -0.1167 | -0.1167 | 0.0003 | 0.2001 | 0.0011 | 0.155 | 0.0689 | 1,192.80 | -41.89 | -47.65 | -45.33 | -51.12 | -1,010.23 | -- | -39,248.79 | -13,980.33 | 2.65 | -- | 0.058 | -- | -59.07 | -- | 18.80 | -- | -19.38 | -- |
Eupraxia Pharmaceuticals Inc | 0.00 | -42.38m | 138.75m | 29.00 | -- | 5.12 | -- | -- | -1.68 | -1.68 | 0.00 | 0.7599 | 0.00 | -- | -- | 0.00 | -122.29 | -127.84 | -185.74 | -935.99 | -- | -- | -- | -- | -- | -85.63 | 0.3455 | -- | -- | -- | -52.63 | -- | -7.69 | -- |
Medicenna Therapeutics Corp | 0.00 | -25.47m | 157.66m | 16.00 | -- | 27.63 | -- | -- | -0.3657 | -0.3657 | 0.00 | 0.0745 | 0.00 | -- | -- | 0.00 | -91.64 | -54.93 | -104.12 | -60.91 | -- | -- | -- | -- | -- | -2.75 | 0.00 | -- | -- | -- | -153.44 | -- | -- | -- |
NervGen Pharma Corp | 0.00 | -20.02m | 196.76m | 10.00 | -- | 10.40 | -- | -- | -0.3363 | -0.3363 | 0.00 | 0.2692 | 0.00 | -- | -- | -- | -78.68 | -121.15 | -138.24 | -180.20 | -- | -- | -- | -- | -- | -9.07 | 0.0092 | -- | -- | -- | -8.01 | -- | 2.20 | -- |
Cardiol Therapeutics Inc | 0.00 | -30.22m | 217.26m | 17.00 | -- | 10.65 | -- | -- | -0.4622 | -0.4622 | 0.00 | 0.2938 | 0.00 | -- | -- | -- | -72.11 | -58.97 | -91.89 | -68.62 | -- | -- | -- | -158,738.10 | -- | -- | 0.0083 | -- | -- | -- | 9.06 | -- | 36.06 | -- |